An Estimation of HIV/AIDS’s Cost in the Voluntary Counseling and Testing Center of Imam Khomeini Hospital in 2010-2011
DOI:
https://doi.org/10.12970/2309-0529.2018.06.07Keywords:
HIV, AIDS, Cost.Abstract
Introduction: Undoubtedly, HIV/AIDS is one of the most important emerging infectious disease in the late twentieth century; and its control is possible only with proper and organized program. To attain this goal, one of the most serious issues is the budget planning and distribution. The present study calculated the total costs of AIDS in Voluntary Counseling and Testing center of Imam Khomeini Hospital in 2010-2011.Methods: The total cost of AIDS at this center was divided into four categories: health care, training and educating, research and services. All costs for 2010-2011 were extracted and classified based on documents and bills which were found in the center.
Results: According to the calculations, the center had a total of 6,603,479,058 IRR in 2010-2011, of which 49.5% (3,271,089,796 IRR) was allocated for health care expenditure, 20.3% (1,335,186,000 IRR) for research, 12.6% (834,000,000 IRR) for training and 17.6% (1,163,203,262 IRR) for services. The average expense for each person living with HIV was 2276 US dollars. The cost of treatment by drugs for each person eligible for treatment was 782 US dollars.
Conclusion: The percentage of budget distribution in the center is equal to the same percentage in low and middle income countries; although, more percentage is allocated for research than the mentioned countries. Also, the expenditure spent for treatment by drugs is more than the average of the same found in low and middle income countries. Overall, the budget distribution in this center is almost in accordance with the international standards.
References
[1] Levy AR, James D, Johnston KM, Hogg RS, Harrigan PR, Harrigan BP, et al. The direct costs of HIV/AIDS care. The Lancet Infectious Diseases 2006; 6(3): 171-7. https://doi.org/10.1016/S1473-3099(06)70413-3
[2] Organization WH. Global report: UNAIDS report on the global AIDS epidemic 2013.
[3] Krentz HB, Gill MJ. The Direct Medical Costs of Late Presentation. AIDS research and treatment 2011; 2012.
[4] Montaner JS, Hogg RS, Weber AE, Anis AH, O'Shaughnessy MV, Schechter MT. The costs of triple-drug anti-HIV therapy for adults in the Americas. JAMA: The Journal of the American Medical Association 1998; 279(16): 1263-4. https://doi.org/10.1001/jama.279.16.1259
[5] Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD. Costs of HIV medical care in the era of highly active antiretroviral therapy. Aids 1999; 13(8): 963-9. https://doi.org/10.1097/00002030-199905280-00013
[6] Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. JAIDS Journal of Acquired Immune Deficiency Syndromes 1997; 16(1): 54-62. https://doi.org/10.1097/00042560-199709010-00009
[7] Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC, Lebrun T, Paltiel AD, et al. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antiviral Therapy 2002; 7(4): 257-66.
[8] Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 05.
[9] Beck EJ, Miners AH, Tolley K. The cost of HIV treatment and care. Pharmacoeconomics 2001; 19(1): 13-39. https://doi.org/10.2165/00019053-200119010-00002
[10] Latest statistics on HIV/AIDS infection in Islamic Republic of Iran. Ministry of Health and Medical Education, Center for Disease Control 2012; [in persian].
[11] Dodds C, Colman R, Amaratunga C, Wilson J. The Cost of HIV/AIDS in Canada. GPI Atlantic, Halifax 2000.
[12] Sardashti S, Samaei M, Firouzeh MM, Mirshahvalad SA, Pahlaviani FG, SeyedAlinaghi S. Early initiation of antiretroviral treatment: Challenges in the Middle East and North Africa. World J Virol 2015; 4(2): 134-41. https://doi.org/10.5501/wjv.v4.i2.134
